Skip to search formSkip to main contentSkip to account menu

MK 383

Known as: MK-383 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Several preclinical studies have found a poor correlation between the ex vivo platelet inhibitory potency and the in vivo… 
2002
2002
The platelet integrin αIIb β3 (GPIIb/IIIa) acts as a receptor for fibrinogen, playing a critical role in platelet aggregation… 
Review
1999
Review
1999
  • C. Dyke
  • American heart journal
  • 1999
  • Corpus ID: 33198754
Platelet-mediated coronary thrombosis is the primary pathophysiologic mechanism of acute coronary syndromes (ACS) and acute… 
1999
1999
In vivo antithrombotic efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) was studied with respect to their… 
1997
1997
We determined the effects of combining the glycoprotein IIb/IIIa inhibitor tirofiban (MK-383, Aggrastat) and ticlopidine on… 
Highly Cited
1994
Highly Cited
1994
MK‐383 (L‐tyrosine, N‐n‐butylsulfonyl)‐O‐[4‐butyl(4‐piperidinyl)], monohydrochloride monohydrate) is a potent and specific… 
Highly Cited
1993
Highly Cited
1993
BackgroundFibrinogen-dependent cross-linking of glycoprotein (GP) lIb/IIIa on activated platelets is the final mechanism leading…